{"title":"MASLD与肝外癌症风险的关系：18项队列研究的系统回顾和荟萃分析。","authors":"Ben-Gang Zhou, Xin Jiang, Qiang She, Yan-Bing Ding","doi":"10.1111/eci.14276","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Numerous recent studies have explored the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of various extrahepatic cancers. However, the conclusions were inconclusive. The aim of this study was to clarify this relationship by conducting a robust meta-analysis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Systematic searches were conducted on PubMed, Embase and Web of Science databases to identify relevant cohort studies published prior to February 2024. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were combined using a random-effects model in this meta-analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eighteen cohort studies (approximately 16.7 million participants) were finally included in this meta-analysis. MASLD was linked to a higher risk of extrahepatic cancers, such as gastric (<i>n</i> = 10, HR = 1.47, 95% CI: 1.07–2.01), colorectal (<i>n</i> = 13, HR = 1.33, 95% CI: 1.16–1.53), pancreatic (<i>n</i> = 8, HR = 1.41, 95% CI: 1.11–1.79), biliary tract (<i>n</i> = 5, HR = 1.27, 95% CI: 1.18–1.37), thyroid (<i>n</i> = 6, HR = 1.46, 95% CI: 1.02–2.09), urinary system (<i>n</i> = 10, HR = 1.45, 95% CI: 1.25–1.69), breast (<i>n</i> = 11, HR = 1.17, 95% CI: 1.08–1.26) and female genital organ cancers (<i>n</i> = 10, HR = 1.36, 95% CI: 1.11–1.66). However, there was no statistically significant association between MASLD and the risk of head and neck (<i>n</i> = 6, HR = 1.03, 95% CI: 99–1.07), oesophageal (<i>n</i> = 9, HR = 1.26, 95% CI: 0.86–1.86), lung (<i>n</i> = 9, HR = 1.01, 95% CI: 0.92–1.10), prostate (<i>n</i> = 9, HR = 1.06, 95% CI: 0.94–1.19) or small intestine cancer (<i>n</i> = 2, HR = 1.75, 95% CI: 1.00–3.06).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This latest large-scale meta-analysis indicated that MASLD was associated with an increased risk of various extrahepatic cancers, such as gastric, colorectal, pancreatic, biliary duct, thyroid, urinary system, breast, skin and female genital cancers. Further research is needed to investigate the mechanisms underlying these associations.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"54 11","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies\",\"authors\":\"Ben-Gang Zhou, Xin Jiang, Qiang She, Yan-Bing Ding\",\"doi\":\"10.1111/eci.14276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Numerous recent studies have explored the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of various extrahepatic cancers. However, the conclusions were inconclusive. The aim of this study was to clarify this relationship by conducting a robust meta-analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Systematic searches were conducted on PubMed, Embase and Web of Science databases to identify relevant cohort studies published prior to February 2024. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were combined using a random-effects model in this meta-analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Eighteen cohort studies (approximately 16.7 million participants) were finally included in this meta-analysis. MASLD was linked to a higher risk of extrahepatic cancers, such as gastric (<i>n</i> = 10, HR = 1.47, 95% CI: 1.07–2.01), colorectal (<i>n</i> = 13, HR = 1.33, 95% CI: 1.16–1.53), pancreatic (<i>n</i> = 8, HR = 1.41, 95% CI: 1.11–1.79), biliary tract (<i>n</i> = 5, HR = 1.27, 95% CI: 1.18–1.37), thyroid (<i>n</i> = 6, HR = 1.46, 95% CI: 1.02–2.09), urinary system (<i>n</i> = 10, HR = 1.45, 95% CI: 1.25–1.69), breast (<i>n</i> = 11, HR = 1.17, 95% CI: 1.08–1.26) and female genital organ cancers (<i>n</i> = 10, HR = 1.36, 95% CI: 1.11–1.66). However, there was no statistically significant association between MASLD and the risk of head and neck (<i>n</i> = 6, HR = 1.03, 95% CI: 99–1.07), oesophageal (<i>n</i> = 9, HR = 1.26, 95% CI: 0.86–1.86), lung (<i>n</i> = 9, HR = 1.01, 95% CI: 0.92–1.10), prostate (<i>n</i> = 9, HR = 1.06, 95% CI: 0.94–1.19) or small intestine cancer (<i>n</i> = 2, HR = 1.75, 95% CI: 1.00–3.06).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>This latest large-scale meta-analysis indicated that MASLD was associated with an increased risk of various extrahepatic cancers, such as gastric, colorectal, pancreatic, biliary duct, thyroid, urinary system, breast, skin and female genital cancers. Further research is needed to investigate the mechanisms underlying these associations.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":\"54 11\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/eci.14276\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14276","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies
Background
Numerous recent studies have explored the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of various extrahepatic cancers. However, the conclusions were inconclusive. The aim of this study was to clarify this relationship by conducting a robust meta-analysis.
Methods
Systematic searches were conducted on PubMed, Embase and Web of Science databases to identify relevant cohort studies published prior to February 2024. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were combined using a random-effects model in this meta-analysis.
Results
Eighteen cohort studies (approximately 16.7 million participants) were finally included in this meta-analysis. MASLD was linked to a higher risk of extrahepatic cancers, such as gastric (n = 10, HR = 1.47, 95% CI: 1.07–2.01), colorectal (n = 13, HR = 1.33, 95% CI: 1.16–1.53), pancreatic (n = 8, HR = 1.41, 95% CI: 1.11–1.79), biliary tract (n = 5, HR = 1.27, 95% CI: 1.18–1.37), thyroid (n = 6, HR = 1.46, 95% CI: 1.02–2.09), urinary system (n = 10, HR = 1.45, 95% CI: 1.25–1.69), breast (n = 11, HR = 1.17, 95% CI: 1.08–1.26) and female genital organ cancers (n = 10, HR = 1.36, 95% CI: 1.11–1.66). However, there was no statistically significant association between MASLD and the risk of head and neck (n = 6, HR = 1.03, 95% CI: 99–1.07), oesophageal (n = 9, HR = 1.26, 95% CI: 0.86–1.86), lung (n = 9, HR = 1.01, 95% CI: 0.92–1.10), prostate (n = 9, HR = 1.06, 95% CI: 0.94–1.19) or small intestine cancer (n = 2, HR = 1.75, 95% CI: 1.00–3.06).
Conclusions
This latest large-scale meta-analysis indicated that MASLD was associated with an increased risk of various extrahepatic cancers, such as gastric, colorectal, pancreatic, biliary duct, thyroid, urinary system, breast, skin and female genital cancers. Further research is needed to investigate the mechanisms underlying these associations.
期刊介绍：
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
